December 1, 2022 JAMA Oncol. Published online December 1, 2022. doi:10.1001/jamaoncol.2022.6138 Full Text To the Editor We read with interest the editorial interpretation by Ahn et al1 of the A021501 trial2 but disagree with the authors’ conclusions. Radiation therapy has been a central component of neoadjuvant trials for pancreatic cancer (PC)3 for more than a decade; however, the duration of neoadjuvant chemotherapy and optimal radiation dose remain unanswered.